Henrik Gréen (0000-0002-8015-5728)

Personal information

Biography

2020 - Professor at Linköping University
2012 - Molecular Biologist in Engineering and Genomics. Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping.
2012 Associate Professor in Pharmacogenetics at Linköping University
2011-2012 Post-doc at Science for Life Laboratory, Division of Gene technology, Institution for Biotechnology, KTH - Royal Institute of Technology.
2007-2012 Assistant Professor at the Division of Drug Research, LiU
2007 PhD in Clinical Pharmacology, Division of Clinical Pharmacology, Linköping University
2000 Master of Science in Engineering Biology, Linköping University

Activities

Collapse all

Linköping University: Linköping, SE

2020-10-01 to present | Professor (Department of Biomedical and Clinical Sciences)

Employment

Henrik Gréen

https://orcid.org/0000-0002-8015-5728

Personal information

Emails & domains

Verified email domains

Websites & social links

Other IDs

Keywords

Countries

Biography

Activities

Employment (2)

Linköping University: Linköping, SE

National board of forensic medicine: Linköping, SE

Education and qualifications (1)

Linköpings Universitet Avdelningen för läkemedelsforskning: Linköping, SE

Professional activities (2)

The International Association of Forensic Toxicologists: Oxford, GB

International Society for Forensic Genetics: New York, NY, US

Funding (4)

Pharmacogenetic studies for personalized chemotherapy

Strategic initiative in pharmacogenetics: from discovery to implementation

Massive parallel sequencing and genotyping strategies for prediction of chemotherapy induced adverse drug reactions

Studies to identify new candidate genes for individualized chemotherapy of lung and ovarian cancer

Works (50 of 139)

Human metabolism of the semi‐synthetic cannabinoids hexahydrocannabinol, hexahydrocannabiphorol and their acetates using hepatocytes and urine samples

In vitro metabolism of Benzyl-4CN-BUTINACA and MDMB-4CN-BUTINACA using human hepatocytes and LC-QToF-MS analysis

Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples

Log D7.4 and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity

In vitro metabolism study of ADB‐P‐5Br‐INACA and ADB‐4en‐P‐5Br‐INACA using human hepatocytes, liver microsomes, and in‐house synthesized references

Des-acyl ghrelin reduces alcohol intake and alcohol-induced reward in rodents

In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs

In vitro activation of the CB1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P)

Postmortem metabolomics as a high-throughput cause-of-death screening tool for human death investigations

Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing

Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method

Enhancer mutations modulate the severity of chemotherapy-induced myelosuppression

Pharmacological profile, phase I metabolism, and excretion time profile of the new synthetic cathinone 3,4‐Pr‐PipVP

Biomarkers and Proteomics in Sarcomeric Hypertrophic Cardiomyopathy in the Young—FGF-21 Highly Associated with Overt Disease

Impact of resection margins and para-aortic lymph node metastases on recurrence patterns and prognosis in resectable pancreatic cancer – a long-term population-based cohort study

The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards

In vitro metabolite identification of acetylbenzylfentanyl, benzoylbenzylfentanyl, 3‐fluoro‐methoxyacetylfentanyl, and 3‐phenylpropanoylfentanyl using LC‐QTOF‐HRMS together with synthesized references

Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor

Long-QT mutations in KCNE1 modulate the 17β-estradiol response of Kv7.1/KCNE1

Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC-MS-MS.

Metabolism studies of 4'Cl-CUMYL-PINACA, 4'F-CUMYL-5F-PINACA and 4'F-CUMYL-5F-PICA using human hepatocytes and LC-QTOF-MS analysis.

Postmortem Metabolomics of Insulin Intoxications and the Potential Application to Find Hypoglycemia-Related Deaths

Whole exome sequencing of FFPE samples-expanding the horizon of forensic molecular autopsies.

Early changes in gene expression profiles in AML patients during induction chemotherapy

Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis.

Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.

Early changes in gene expression profiles in AML patients during induction chemotherapy

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes

Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions

The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine.

Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays.

Postmortem Metabolomics Reveal Acylcarnitines as Potential Biomarkers for Fatal Oxycodone-Related Intoxication

The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons.

The Importance of BHB Testing on the Post-Mortem Diagnosis of Ketoacidosis

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.

Circumstances, Postmortem Findings, Blood Concentrations and Metabolism in a Series of Methoxyacetylfentanyl-Related Deaths.

Characteristics of post-mortem beta-hydroxybutyrate-positivet cases - A retrospective study on age, sex and BMI in 1407 forensic autopsies.

Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort.

JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity.

Post-Mortem Metabolomics: A Novel Approach in Clinical Biomarker Discovery and a Potential Tool in Death Investigations.

Technical in-depth comparison of two massive parallel DNA-sequencing methods for formalin-fixed paraffin-embedded tissue from victims of sudden cardiac death.

A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood.

Heroin-Related Compounds and Metabolic Ratios in Postmortem Samples Using LC-MS-MS.

Oxycodone findings and CYP2D6 function in postmortem cases.

Oxycodone Concentrations and Metabolic Ratios in Femoral Blood from Fatal Intoxications and Other Causes of Death using LC-MS-MS.

Real World Evaluation of Upfront Docetaxel in Metastatic Castrate Sensitive Prostate Cancer

Activation of the μ‐opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure

High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young.

Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS, Hepatocyte Incubations and Synthesized Reference Standards.

In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects

Peer review (2 reviews for 1 publication/grant)